PharmaShots | Incisive News in 3 Shots

Subscribe Now

Jardiance

Eli Lilly and Boehringer Ingelheim Report the P-III (EMPACT-MI) Study Data of Jardiance on Risk of Heart Failure and Death Following a Heart Attack

Eli Lilly and Boehringer Ingelheim Report the P-III (EMPACT-MI) Study Data of Jardiance on Risk of Heart Failure and Death Followi...

April 8, 2024

Insights+: EMA Marketing Authorization of New Drugs in December 2023

Insights+: EMA Marketing Authorization of New Drugs in December 2023

January 23, 2024

Unlocking Approval: Mohamed Eid Dives into the Exciting Approval of Jardiance for Adult CKD Treatment in a Captivating Chat with PharmaShots

Unlocking Approval: Mohamed Eid Dives into the Exciting Approval of Jardiance for Adult CKD Treatment in a Captivating Chat with P...

December 6, 2023

Boehringer Ingelheim’s Jardiance Receives NICE Recommendation for Symptomatic Chronic Heart Failure with Preserved or Mildly Reduced Ejection Fraction

Boehringer Ingelheim’s Jardiance Receives NICE Recommendation for Symptomatic Chronic Heart Failure with Preserved or Mildly Reduc...

October 6, 2023

Boehringer Ingelheim and Eli Lilly Receive the US FDA’s Approval of Jardiance (empagliflozin) for Adults with Chronic Kidney Disease

Boehringer Ingelheim and Eli Lilly Receive the US FDA’s Approval of Jardiance (empagliflozin) for Adults with Chronic Kidney Disea...

September 25, 2023

Insights+: EMA Marketing Authorization of New Drugs in July 2023

Insights+: EMA Marketing Authorization of New Drugs in July 2023

August 25, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us